Bio-techne Stock News

The Glycobiology Market report focus on the current trends of the request along with detailed analysis which provides data regarding this request rate, and it also predicts the unborn request growth rate. The Glycobiology Market study includes exploration on the

Related Stocks: DFS , FANG , PGNY , RCL , BILL , SGEN , AVLR , TECH , ROKU , FOUR , PINS , LPLA , VEEV , PCTY , TTWO , ELS , SPOT , ZEN , FICO , FIVN , NVRO , EXAS ,

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

Brokerages forecast that Bio-Techne Co. (NASDAQ:TECH) will announce $267.04 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Bio-Technes earnings. The lowest sales estimate is $263.81 million and the highest is $268.70 million. Bio-Techne posted sales of $224.25 million during the same quarter last year, which suggests a []

Kashmir Latest News, Kashmir News, Kashmir, Horizon, Srinagar, Jammu Jammu| Dec,16: To suffice the requirements of the officers and other ranks of Central Pool Jammu, Dr S.D Singh Jamwal Addl. DGP Security, J&K, inaugurated a renovated Conference Hall and the Barber Shop in the premises of Security Central Pool Jammu. R.S. Sambyal SSP (Tech), R.P. Singh JKPS SSP Staff Officer and Farooq Ahmad Pvt. [] DGP Security inaugurates facility for officers, other ranks The Kashmir Horizon .

Geneva Capital Management LLC lessened its position in Bio-Techne Co. (NASDAQ:TECH) by 25.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 264,307 shares of the biotechnology companys stock after selling 88,674 shares during the period. Bio-Techne accounts for 2.2% of Geneva []

Related Stocks: MRNA , BIIB , VRTX , ICLR , TECH , NTRA , NTLA , ALXN , NBIX , QDEL , IONS ,

Hills Bank & Trust Co decreased its stake in Bio-Techne Co. (NASDAQ:TECH) by 2.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 4,455 shares of the biotechnology companys stock after selling 90 shares during the period. Hills Bank & Trust Cos holdings in Bio-Techne were worth $2,159,000 at the end of the most []

Sector ETF report for PBE

The Tissue Microarray Market 2021 report provides a 360-degree survey of all sections responsible for the development of the Tissue Microarray market. The industry research explores the current fierce situation and the changing factors of the various factors that influence

The Glycobiology Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Glycobiology Market study includes research on the

Sumitomo Mitsui Trust Holdings Inc. reduced its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 222,228 shares of the biotechnology companys stock after selling 12,718 shares during the period. Sumitomo []

Zacks Investment Research downgraded shares of Bio-Techne (NASDAQ:TECH) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, []